Limitations of C5 inhibition in the treatment of PNH have recently been highlighted in the Phase III clinical trial (NCT03500549) in which pegcetacoplan and eculizumab were compared (84). The gene discussed is C5; the disease is paroxysmal nocturnal hemoglobinuria.